Steve Wedge

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (12)

John Lunec

UNITED KINGDOM

View details

Celine Cano

Reader in Medicinal Chemistry

Newcastle University

UNITED KINGDOM

View details

Gareth J. Veal

UNITED KINGDOM

View details

Bernard T. Golding

UNITED KINGDOM

View details

Duncan Miller

UNITED KINGDOM

View details

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

View details

Benjamin Cons

Astex Pharmaceuticals

UNITED KINGDOM

View details

Chris Plummer

Honorary Senior Lecturer

Newcastle University

UNITED KINGDOM

View details

Richard Noble

Newcastle University

UNITED KINGDOM

View details

Ian Hickson

Professor of Drug Discovery Bioscience

Newcastle University

UNITED KINGDOM

View details

Elaine Willmore

Newcastle University

UNITED KINGDOM

View details

Jane Endicott

Prof of Cancer Structural Biology

Newcastle University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Steve Wedge

Research Interests

Explore related searches

Contact this professor

Articles (9)

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.

Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Collaborators (12)

John Lunec

Celine Cano

Gareth J. Veal

Bernard T. Golding

Duncan Miller

Ruth Plummer

Benjamin Cons

Chris Plummer

Richard Noble

Ian Hickson

Elaine Willmore

Jane Endicott

Make your next move.